COMPANY

Tyra Biosciences

HQ: Carlsbad, CA source · tyra.bio ↗ · West Coast

Keywords: oncology cancer small molecule FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration FGFR3 Gene Mutation Low Grade Upper Tract Urothelial Carcinoma Achondroplasia Low-grade NMIBC FGFR3 Gene Fusions Metastatic Hepatocellular Carcinoma FGFR4 Gene Mutation FGFR4 Gene Fusions FGF19 Gene Amplification FGF19 Gene Overexpression Locally Advanced Unresectable Hepatocellular Carcinoma Locally Advanced Cholangiocarcinoma Intrahepatic Cholangiocarcinoma Metastatic Cholangiocarcinoma Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Urothelial Carcinoma Bladder Cancer Non-muscle-invasive Bladder Cancer Advanced Urothelial Carcinoma Urinary Tract Cancer Urinary Tract Tumor Urinary Tract Carcinoma Dabogratinib (TYRA-300) Dabogratinib (TYRA-300) TBD TYRA-300 TYRA-430

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

$400.0MRaised (2 yrs)7Trials (company is sponsor)

Timeline

Sep 14, 2026 Raise Follow-on offering: $400M (total, as published), announced Sep 14, 2026. Source: SEC filing. source ↗
Dec 22, 2025 Trial start 2A: Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma source ↗
Jun 27, 2025 Trial start Phase 2: Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer source ↗
Apr 24, 2025 Trial start Phase 1: Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations source ↗
Mar 4, 2025 Trial start Phase 2: A Study of TYRA-300 in Children With Achondroplasia: BEACH301 source ↗
Nov 22, 2023 Trial start Phase 1: Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations source ↗
Oct 16, 2023 Trial start Phase 1: A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants source ↗
Nov 22, 2022 Trial start Phase 1/Phase 2: Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 1/Phase 2 · Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations · NCT05544552
2028-01 (ESTIMATED) · Phase 1 · Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations · NCT06915753
2028-02 (ESTIMATED) · Phase 2 · Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer · NCT06995677
2030-01 (ESTIMATED) · Phase 2 · A Study of TYRA-300 in Children With Achondroplasia: BEACH301 · NCT06842355
2030-10 (ESTIMATED) · 2A · Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma · NCT07265947

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $400.0M. Last 2 years.

Sep 14, 2026 Follow-on offering: $400M (total, as published), announced Sep 14, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07265947	Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma	2A	Recruiting	Dec 22, 2025	2030-10 (estimated)
NCT06842355	A Study of TYRA-300 in Children With Achondroplasia: BEACH301	Phase 2	Recruiting	Mar 4, 2025	2030-01 (estimated)
NCT06995677	Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer	Phase 2	Recruiting	Jun 27, 2025	2028-02 (estimated)
NCT06915753	Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations	Phase 1	Recruiting	Apr 24, 2025	2028-01 (estimated)
NCT06160752	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations	Phase 1	Active, not recruiting	Nov 22, 2023	2026-09 (estimated)
NCT05544552	Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	Phase 1/Phase 2	Active, not recruiting	Nov 22, 2022	2026-11 (estimated)
NCT06006702	A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants	Phase 1	Active, not recruiting	Oct 16, 2023	2025-05 (estimated)